[A23-73] Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V
Last updated 16.10.2023
Project no.:
A23-73
Commission:
Commission awarded on 14.07.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment
- Patients who have had an inadequate response with, lost response to, or are intolerant to conventional therapy: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or are intolerant to biologic treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-73